Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections

Pathology

Volumn 35, Issue 6, 2003, Pages 513-517

  Bismar, Tarek A ^a   Bianco, Fernando J ^a   Zhang, Hongquan ^a   Li, Xingli ^a   Sarkar, Fazlul H ^a   Sakr, Wael A ^a   Grignon, David J ^a   Che, Mingxin ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

G250; Real time RT PCR; Renal cell carcinoma

Indexed keywords

CARBONATE DEHYDRATASE IX; MESSENGER RNA; PARAFFIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CHROMOPHOBE ADENOMA; CLEAR CELL CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; MAJOR CLINICAL STUDY; NEPHRECTOMY; ONCOCYTOMA; PAPILLARY CARCINOMA; PREDICTION; PROGNOSIS; RELIABILITY; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TATA BOX;

EID: 0348047338     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313020310001619910     Document Type: Article

References (22)

1. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000; 85: 865-70.
2. Zavada J, Zavadova Z, Pastorek J, et al. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 2000; 82: 1808-13.
3. Opavsky R, Pastorekova S, Zelnik V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996; 33: 480-7.
4. Oosterwijk E, Debruyne FM, Schalken JA. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin Oncol 1995; 22: 34-41.
5. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4: 2729-39.
6. Kranenborg MH, Boerman OC, de Weijert MC, et al. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts. Cancer 1997; 80: 2390-7.
7. van Dijk J, Uemura H, Beniers AJ, et al. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int J Cancer 1994; 56: 262-8.
8. Godfrey TE, Kim SH, Chavira M, et al. Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5′ nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn 2001; 2: 84-91.
9. Specht K, Richter T, Muller U, Walch A, Hofler MW. Quantitative gene expression analysis in microdissected archival tissue by real-time RT-PCR. J Mol Med 2000; 78: B27.
10. Specht K, Richter T, Muller U, et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001; 158: 419-29.
11. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Centre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 987-9.
12. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-63.
13. Chuanzhong Y, Ming G, Fanglin Z, et al. Real-time quantitative reverse transcription-PCR assay for renal cell carcinoma-associated antigen G250. Clin Chim Acta 2002; 318: 33-40.
14. Specht K, Kremer M, Muller U, et al. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections. Clin Cancer Res 2002; 8: 2902-11.
15. McKiernan JM, Buttyan R, Bander NH, et al. Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res 1997; 57: 2362-5.
16. Saarnio J, Parkkila S, Parkkila AK, et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 1998; 153: 279-85.
17. Pastorekova S, Parkkila S, Parkkila AK, et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997; 112: 398-408.
18. Murakami Y, Kanda K, Tsuji M, Kanayama H, Kagawa S. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 1999; 83: 743-7.
19. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999; 81: 741-6.
20. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-11.
21. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997; 57: 2827-31.
22. Li G, Passebosc-Faure K, Lambert C, et al. The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells. Clin Cancer Res 2001; 7: 89-92.